Lakshmanan, Arun Prasath <br/><br/>
Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.  [electronic resource] 

 -  Molecular and cellular endocrinology  Jan 2012 
 - 104-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-8057 
<br/><br/><label>Standard No.: </label>10.1016/j.mce.2011.07.041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiotensin II Type 1 Receptor Blockers--pharmacology<br/>Angiotensin-Converting Enzyme 2<br/>Animals<br/>Apoptosis--drug effects<br/>Diabetes Mellitus, Experimental<br/>Diabetic Nephropathies--prevention & control<br/>Enzyme Activation<br/>Gene Expression<br/>Imidazoles--pharmacology<br/>Intracellular Signaling Peptides and Proteins--metabolism<br/>Kidney--drug effects<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Oxidative Stress<br/>Peptidyl-Dipeptidase A--genetics<br/>Phosphorylation<br/>Protein Serine-Threonine Kinases--metabolism<br/>Proto-Oncogene Mas<br/>Proto-Oncogene Proteins--genetics<br/>Receptor, Angiotensin, Type 1--metabolism<br/>Receptors, G-Protein-Coupled--genetics<br/>Tetrazoles--pharmacology<br/>p38 Mitogen-Activated Protein Kinases--metabolism